Kymera Therapeutics (KYMR) News Today

Kymera Therapeutics, Inc. (NASDAQ: KYMR) shares have recently moved higher despite a cautious round of analyst estimate revisions. The main tension for investors is strong recent operating momentum versus expectations for continued heavy investment and losses.

• Positive Sentiment: Brookline Capital Markets maintained its Buy rating, indicating that the firm continues to see longer-term value in Kymera’s targeted protein degradation pipeline despite reducing its financial forecasts.
• Positive Sentiment: Kymera’s latest reported quarter provided a favorable backdrop: revenue reached $65.0 million, substantially exceeding the $32.8 million consensus estimate, while its loss of $0.62 per share was narrower than the expected $0.71 loss. Revenue increased more than 465% year over year.
• Neutral Sentiment: HC Wainwright now forecasts a $3.40-per-share loss for fiscal 2026, broadly in line with the current consensus loss estimate of $3.44. The firm also projects a return to positive EPS of $0.22 in fiscal 2030, suggesting potential long-term profitability.
• Negative Sentiment: HC Wainwright reduced its EPS estimates for the third and fourth quarters of 2026 to losses of $1.04 and $1.02, respectively, from prior forecasts of $0.69 and $0.68 losses. It also lowered estimates for fiscal 2027 through 2029, with the fiscal 2029 forecast falling to a $3.70 loss from a $2.65 loss.
• Negative Sentiment: Brookline Capital Markets made similar reductions, cutting its fiscal 2026 EPS estimate to a $3.97 loss and lowering its forecasts for fiscal 2027, 2028 and 2029 to losses of $5.28, $6.18 and $5.61 per share, respectively.
• Negative Sentiment: HC Wainwright’s fiscal 2028 and 2030 revisions were also notably weaker: its fiscal 2028 loss estimate widened to $4.32 per share from $3.30, while its fiscal 2030 profit forecast dropped to $0.22 from $1.07. The broad reductions point to expectations for higher costs or slower earnings conversion, which could limit upside if pipeline progress does not accelerate.

Overall, the stock’s positive reaction appears supported by strong revenue growth, a recent earnings beat and continued analyst confidence in Kymera’s pipeline. However, the repeated estimate cuts highlight elevated execution risk and a longer path to profitability.